Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis
NCT00049751 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior disease-modifying antirheumatic drugs (DMARDs).
Conditions Studied
Interventions
- DRUG Adalimumab
Study Locations (20)
California
- Desert Valley Medical — Apple Valley
- Kenneth Hsu, MD, Inc. — Bakersfield
- Rheumatology Clinic — Los Angeles
- Michael Harrington, MD — Napa
- Midori Jane Nishio, MD — Walnut Creek
- Naveen Raja, MD — Whittier
Illinois
- Loyola University Medical Center — Maywood
- West Suburban Health Care — Oak Park
- OSF Medical Group -Rheumatology — Peoria
- Rockford Clinic, Clinical Research Department — Rockton
- Pain Therapy Center — Schaumburg
Florida
- Norman Gaylis, MD — Aventura
- Mike Schweitz, MD — West Palm Beach
- Maurice McCarthy, MD — Winter Haven
Connecticut
- Division of Rheumatic Diseases/University of CT Health Center — Farmington
- New Haven Medical Group, PC — New Haven
Idaho
- Intermountain Orthopedics — Boise
- Institute of Arthritis Research — Idaho Falls
Alabama
- Thomas McGee, MD — Mobile
Colorado
- Mountain Rheumatology — Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2002-09 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049751
The ClinicalTrials.gov registry entry for NCT00049751 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 43 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention — of which Adalimumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00049751 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Illinois, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00049751 about?
NCT00049751 is a clinical study titled "Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis". The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior disease-modifying antirheumatic drugs (DMARDs).
What is the current status of trial NCT00049751?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,000 participants. The study started on 2002-09.
What conditions does trial NCT00049751 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00049751?
The interventions under investigation include: Adalimumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00049751?
This trial is sponsored by Abbott, which has 43 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00049751 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.